DENOSUMAB
Approved April 2018 only for treatment of hypercalcemia of malignancy in the setting of severe renal failure or for patients who are refractory to any bisphosphonate.
Approved April 2018 only for treatment of hypercalcemia of malignancy in the setting of severe renal failure or for patients who are refractory to any bisphosphonate.